travere.com (TVTX) - Market Value to Book Value Ratio

Travere Therapeutics Inc (TVTX) - corporate logo

Partners' specialized facilities ensure the stable production of nephrological agents, and their technical reliability guarantees supplies. Travere Therapeutics (TVTX) maintains the status of a reliable ally for patients with rare kidney pathologies by creating life-saving therapies. The current figure is 192.51. This historical price chart confirms that the business relies on outsourced production and logistics, creating a significant dependency on external vendors.

Travere Corp (TVTX) - Market Value to Book Value from 07/04/2022 to 10/31/2026

Travere Therapeutics Inc (TVTX) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Stock Quotes Travere Therapeutics|TVTX - Broker Consensus Forecast
- market capitalization indicators:
Market Value Retrophin|TVTX - Full Business Value
- book capitalization data:
Book Value per Share Travere Therapeutics|TVTX - Accounting Value of Company|Market Capitalization to Book Value Ratio travere.com|TVTX - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Equity Travere Therapeutics|TVTX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Retrophin|TVTX - Company Total Debt|Debts to Book Capitalization Retrophin|TVTX - Company Long-Term Debts|Company Current Liabilities Travere Therapeutics|Quick Liquidity travere.com
- earnings and valuation multiples indicators:
TVTX - Net Profit
Basic company analysis:Travere Therapeutics - TVTX
Manufactured product of Retrophin

This indicator is calculated as the ratio of the company's market value to its net equity, measuring the market premium over book assets and signaling impairment risks if the value drops below one. The current market value to book value ratio reflects investor expectations for scaling sales of Travere Therapeutics (TVTX) drugs, where increasing operating leverage and R&D cost optimization should capitalize into long-term business value growth.

Competitor analysis

ARDX (Ardelyx, Inc.) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio PROK|Market Value to Book Value Ratio Akebia Therapeutics, Inc.|Cara Therapeutics, Inc. - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio DMAC|UNCY (Unicycive Therapeutics, Inc) - Market Value to Book Value|Market Capitalization to Book Value Ratio RMTI (Rockwell Medical, Inc.)|Market Capitalization to Book Value Ratio cadrenal.com CVKD|CDT - Market Value to Book Value Ratio|Market Value to Book Value CALT (Calliditas Therapeutics)|Renalytix (RNLX) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio ZyVersa Therapeutics, Inc.